Lisa Christopher-Stine, MD, MPH, discussed the latest findings on myositis and its subtypes, including insights into antibodies linked to cancer and treatments for these patients.

Subcategories:Clinical Criteria/GuidelinesEthicsLegal UpdatesLegislation & AdvocacyMeeting ReportsResearch Rheum
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
Lisa Christopher-Stine, MD, MPH, discussed the latest findings on myositis and its subtypes, including insights into antibodies linked to cancer and treatments for these patients.
Michelle Sharp, MD, MHS, shared insights into the complexities of sarcoidosis, describing how she evaluates, diagnoses and treats patients.
Carol A. Langford, MD, MPH |
ACR President Carol A. Langford, MD, MPH, highlights the importance of research in the field and where to find resources and initiatives within the ACR to support, fund, inspire, and enhance innovation. For more on this important topic, see Dr. Langford’s column in the January issue of The Rheumatologist.
Research & patients reap benefits when patients with rheumatic conditions get involved in patient-facing organizations & in clinical research planning.
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.
Carol A. Langford, MD, MHS |
For me, few ACR events bring home our connection as a rheumatology community more than our annual meeting, ACR Convergence. In addition to its many important opportunities for networking and education, one aspect of the meeting that always inspires me is the research. Research represents one of the three priorities of my presidential term because…
In 2024, key federal healthcare regulations and policy developments—related to health insurance, privacy protections, reimbursement, biosimilar use and more—shaped the landscape of the practice of rheumatology in several important ways.
By July 5, all providers who participate in federally funded healthcare programs, including Medicare and Medicaid, must provide language assistance programs for patients to meet requirements of Section 1557 of the Affordable Care Act.
ACR Convergence 2024—Arthritis symptoms related to lupus are a bit of a trouble spot for clinicians, with limited data to guide treatment and overlap with other conditions, experts said in a session at ACR Convergence. Lupus arthritis (LA), present in 95% of patients with lupus, is the main cause of work-related disability and is a…
ACR Convergence 2024—With poor sleep a major complaint among patients with rheumatologic diseases, physicians should hone their understanding of how the body regulates sleep and how this system can be disrupted, and tailor their management plans to help patients with these issues, panelists said in a session at ACR Convergence. For some patients, their struggles…